Evidence map›Paper›PMID 32321824›Full record

ArticlemSphere2020

Host Cathelicidin Exacerbates Group B

Kathryn A Patras, Alison Coady, Priyanka Babu, Samuel R Shing, Albert D Ha, Emma Rooholfada, Stephanie L Brandt, Matthew Geriak, Richard L Gallo, Victor Nizet

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Type 2 diabetes mellitus exacerbates vaginal group BbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Re-framing the importance of Group BInfection and immunity · 2024
    Review
  14. Article
  15. Infection and immunity · 2023
    Article
  16. Review
  17. Enhanced Vulnerability of Diabetic Mice to HypervirulentPathogens (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kathryn A PatrasDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA kathryn.patras@bcm.edu.ORCID 0000-0003-2631-8810
Alison CoadyDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Priyanka BabuDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Samuel R ShingDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Albert D HaDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Emma RooholfadaDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Stephanie L BrandtDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.
Matthew GeriakSharp Memorial Hospital, San Diego, California, USA.
Richard L GalloDepartment of Dermatology, University of California, San Diego, La Jolla, California, USA.
Victor NizetDepartment of Pediatrics, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0003-3847-0422
University of California San Diego · USSharp Memorial Hospital · US

Funding

Cathelicidin in Skin ImmunityR37AI052453 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Richard L Gallo, Victor Nizet · 2019 to 2026
$4.6M
Safety and Dose Optimization of High-Dose Anakinra in Kawasaki DiseaseP50HD090259 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAPPARELLI, EDMUND VINCENT, NIZET, VICTOR · 2019 to 2020
$1.4M
NIAID NIH HHS R37 AI052453NICHD NIH HHS P50 HD090259
6 · The paper itself

Abstract

Group B

Indexed as

Symptom Flare UpAnimalsAntimicrobial Cationic PeptidesCathelicidinsCell LineDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2FemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutPregnancyStreptococcal InfectionsStreptococcusAntimicrobial Cationic PeptidesCathelicidinscathelicidingroup B Streptococcusinnate immunitymast cellurinary tract infection

Identifiers

PMID32321824
PMCPMC7178553
OpenAlexW3020418047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.